REG - SkinBioTherapeutics - Notice of Business Update & Investor Presentation

SkinbiotherapeuticsAnnouncement

15/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240715:nRSO3131Wa&default-theme=true

RNS Number : 3131W  SkinBioTherapeutics PLC  15 July 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Notice of Business Update and Investor Presentation

 

Newcastle, UK - 15 July 2024 - SkinBioTherapeutics plc, (AIM: SBTX), the life
science business focused on skin health, confirms that it will announce an
update on the business on Monday 29 July 2024 and the management team will
make a presentation via the Investor Meet Company platform at 10am on that
day.

 

Questions can be submitted pre-event via the Investor Meet Company
(https://www.investormeetcompany.com/companies/skinbiotherapeutics-plc)
dashboard up to the day before the meeting or at any time during the live
presentation. Investors who already follow SkinBioTherapeutics on the Investor
Meet Company platform will automatically be invited.

 

Investors can sign up to Investor Meet Company for free at this link
(http://www.investormeetcompany.com/companies/skinbiotherapeutics-plc) .

 

-Ends-

 

 

For more information please contact:

 

 SkinBioTherapeutics plc                            Tel: +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Instinctif Partners (Media)                        Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Jack Kincade                SkinBioTherapeutics@instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) and www.axisbiotix.com
(http://www.axisbiotix.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPURWMUPCURC